SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Date Issued
2020
Author(s)
Hoffmann, Markus
Kleine-Weber, Hannah
Schroeder, Simon
Krüger, Nadine
Herrler, Tanja
Erichsen, Sandra
Schiergens, Tobias S.
Herrler, Georg
Wu, Nai-Huei
Nitsche, Andreas
Müller, Marcel A.
Drosten, Christian
DOI
10.1016/j.cell.2020.02.052